MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Bcr‐abl inhibitors suppressed the bcr‐abl‐dependent mTOR signal to inhibit tumorigenesis, but the abl1 mutation and resistance to bcr‐abl inhibitors were observed in patients with CML [57].